Bayesian hierarchical models with calibrated mixtures of g-priors for assessing treatment effect moderation in meta-analysis
以校准的 g 先验混合层级模型估计荟萃分析中的处理效应调节AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接研究随机试验数据中的处理效应调节与异质性,因此归入因果推断。
以校准的 g 先验混合层级模型估计荟萃分析中的处理效应调节AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Assessing treatment effect moderation is critical in biomedical research and many other fields, as it guides personalized intervention strategies to improve participant's outcomes. Individual participant-level data meta-analysis (IPD-MA) offers a robust framework for such assessments by leveraging data from multiple trials. However, its performance is often compromised by challenges such as high between-trial variability. Traditional Bayesian shrinkage methods have gained popularity, but are less suitable in this context, as their priors do not discern heterogeneous studies. In this paper, we propose the calibrated mixtures of g-priors methods in IPD-MA to enhance efficiency and reduce risk in the estimation of moderation effects. Our approach incorporates a trial-level sample size tuning function, and a moderator-level shrinkage parameter in the prior, offering a flexible spectrum of shrinkage levels that enables practitioners to evaluate moderator importance, from conservative to optimistic perspectives. Compared with existing Bayesian shrinkage methods, our extensive simulation studies demonstrate that the calibrated mixtures of g-priors exhibit superior performances in terms of efficiency and risk metrics, particularly under high between-trial variability, high model sparsity, weak moderation effects and correlated design matrices. We further illustrate their application in assessing effect moderators of two active treatments for major depressive disorder, using IPD from four randomized controlled trials.